IDXX
IDEXX Laboratories, Inc. NASDAQ Listed Jun 21, 1991$562.09
+2.93%
vs $546.09
Mkt Cap $45.3B
52w Low $514.61
18.8% of range
52w High $766.68
50d MA $561.85
200d MA $632.52
P/E (TTM)
43.0x
EV/EBITDA
31.1x
P/B
28.0x
Debt/Equity
0.7x
ROE
66.0%
P/FCF
43.0x
RSI (14)
49.50
ATR (14)
$15.50
Beta
1.72
50d MA
$561.85
200d MA
$632.52
Avg Volume
646.2K
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
One IDEXX Drive · Westbrook, ME 04092 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | TNS | 3.41 | 3.47 | +1.8% | 562.97 | -0.2% | +2.9% | -1.2% | -2.1% | -5.0% | +0.4% | — |
| Feb 2, 2026 | TNS | 2.93 | 3.08 | +5.1% | 639.60 | -0.6% | -1.1% | +0.0% | +1.6% | +0.1% | +0.2% | — |
| Nov 3, 2025 | TNS | 3.14 | 3.40 | +8.3% | 722.94 | -0.8% | -0.1% | +0.0% | -0.3% | -0.9% | -0.7% | — |
| Aug 4, 2025 | TNS | 3.28 | 3.63 | +10.7% | 682.78 | -0.9% | -6.0% | +0.0% | -2.8% | +4.1% | +1.2% | — |
| May 1, 2025 | TNS | 2.85 | 2.96 | +3.9% | 471.38 | +1.4% | +0.1% | +0.0% | +0.7% | -0.3% | +2.7% | — |
| Feb 3, 2025 | TNS | 2.39 | 2.62 | +9.6% | 469.04 | -1.0% | -0.9% | +0.0% | +0.8% | -1.7% | -0.2% | — |
| Oct 31, 2024 | TNS | 2.68 | 2.80 | +4.5% | 406.92 | +0.4% | +2.5% | +0.0% | -0.7% | +0.4% | +1.8% | — |
| Aug 6, 2024 | TNS | 2.88 | 3.02 | +4.9% | 469.37 | +0.5% | -0.5% | +0.0% | +3.6% | -0.2% | -0.6% | — |
| May 1, 2024 | TNS | 2.67 | 2.81 | +5.2% | 468.04 | -0.5% | +1.7% | +0.0% | +1.0% | -0.8% | +1.4% | — |
| Feb 5, 2024 | TNS | 2.12 | 2.32 | +9.4% | 572.12 | +0.7% | -0.9% | +0.0% | +0.9% | +0.2% | -0.2% | — |
| Nov 1, 2023 | TNS | 2.37 | 2.53 | +6.8% | 395.35 | +1.5% | +6.1% | +0.0% | +2.4% | -1.5% | -0.1% | — |
| Aug 1, 2023 | TNS | 2.47 | 2.67 | +8.1% | 532.30 | -0.8% | -2.5% | +0.0% | -2.2% | -0.7% | +0.8% | — |
| May 2, 2023 | BMO | 2.42 | 2.55 | +5.4% | 467.38 | +0.9% | +2.4% | +0.0% | -1.9% | +4.0% | -0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | UBS | Maintains | Neutral → Neutral | — | $574.95 | $575.16 | +0.0% | -1.2% | -2.6% | +1.3% | +1.2% | -0.8% |
| Mar 31 | Stifel | Maintains | Buy → Buy | — | $557.09 | $560.04 | +0.5% | +0.9% | +0.5% | +0.9% | +1.4% | -0.5% |
| Feb 9 | Piper Sandler | Maintains | Neutral → Neutral | — | $644.61 | $647.72 | +0.5% | -0.7% | +1.1% | +0.3% | -4.9% | +2.0% |
| Feb 5 | Barclays | Maintains | Overweight → Overweight | — | $642.94 | $643.83 | +0.1% | +0.1% | +0.2% | -0.7% | +1.1% | +0.3% |
| Feb 3 | UBS | Maintains | Neutral → Neutral | — | $639.60 | $635.59 | -0.6% | -1.1% | +1.6% | +0.1% | +0.2% | -0.7% |
| Feb 3 | BTIG | Maintains | Buy → Buy | — | $639.60 | $635.59 | -0.6% | -1.1% | +1.6% | +0.1% | +0.2% | -0.7% |
| Nov 4 | BTIG | Maintains | Buy → Buy | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.3% | -0.9% | -0.7% | +0.2% |
| Nov 4 | JP Morgan | Maintains | Overweight → Overweight | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.3% | -0.9% | -0.7% | +0.2% |
| Nov 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.3% | -0.9% | -0.7% | +0.2% |
| Nov 4 | UBS | Maintains | Neutral → Neutral | — | $722.94 | $717.44 | -0.8% | -0.1% | -0.3% | -0.9% | -0.7% | +0.2% |
| Oct 31 | Stifel | Upgrade | Hold → Buy | — | $628.54 | $634.51 | +0.9% | +0.2% | +14.8% | -0.1% | -0.3% | -0.9% |
| Aug 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $653.95 | $655.54 | +0.2% | -0.5% | -2.0% | -0.2% | +0.5% | -1.1% |
| Aug 11 | Piper Sandler | Maintains | Neutral → Neutral | — | $658.06 | $662.00 | +0.6% | -0.9% | +0.0% | +1.8% | -1.5% | -0.5% |
| Aug 4 | JP Morgan | Maintains | Overweight → Overweight | — | $535.54 | $662.24 | +23.7% | +27.5% | -6.0% | -2.8% | +4.1% | +1.2% |
| Aug 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $535.54 | $662.24 | +23.7% | +27.5% | -6.0% | -2.8% | +4.1% | +1.2% |
| Jul 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $566.50 | $568.90 | +0.4% | +1.2% | -0.2% | -6.6% | +0.2% | +27.5% |
| Jul 17 | Leerink Partners | Maintains | Outperform → Outperform | — | $520.57 | $518.60 | -0.4% | -0.4% | -0.8% | +1.2% | +2.1% | +1.6% |
| Jul 2 | Stifel | Maintains | Hold → Hold | — | $542.65 | $541.48 | -0.2% | +0.0% | +0.8% | -0.3% | -1.2% | +0.3% |
| Jun 11 | Leerink Partners | Maintains | Outperform → Outperform | — | $525.93 | $526.31 | +0.1% | -0.3% | +0.5% | -0.8% | +1.2% | -1.5% |
| May 19 | Stifel | Maintains | Hold → Hold | — | $518.10 | $511.83 | -1.2% | +0.7% | -0.9% | -3.1% | +0.8% | -0.6% |
| May 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $471.90 | $471.90 | +0.0% | +0.7% | -0.3% | +2.7% | +0.7% | +0.4% |
| May 1 | Stifel | Maintains | Hold → Hold | — | $432.65 | $468.18 | +8.2% | +9.0% | +0.1% | +0.7% | -0.3% | +2.7% |
| Apr 21 | BofA Securities | Maintains | Neutral → Neutral | — | $411.49 | $409.47 | -0.5% | -1.2% | +3.7% | +1.2% | +3.4% | -0.8% |
| Apr 15 | Morgan Stanley | Maintains | Overweight → Overweight | — | $404.65 | $404.89 | +0.1% | -0.2% | -0.4% | +2.3% | -1.2% | +3.7% |
| Apr 14 | Stifel | Maintains | Hold → Hold | — | $390.94 | $394.00 | +0.8% | +3.5% | -0.2% | -0.4% | +2.3% | -1.2% |
| Feb 28 | Stifel | Maintains | Hold → Hold | — | $441.03 | $442.01 | +0.2% | -0.9% | +0.0% | +1.0% | -1.0% | -1.9% |
| Feb 10 | Piper Sandler | Maintains | Neutral → Neutral | — | $459.78 | $460.68 | +0.2% | +1.1% | -0.3% | -1.4% | +0.5% | -3.3% |
| Feb 4 | Barclays | Maintains | Overweight → Overweight | — | $469.04 | $464.47 | -1.0% | -0.9% | +0.8% | -1.7% | -0.2% | +1.1% |
| Feb 4 | BofA Securities | Maintains | Neutral → Neutral | — | $469.04 | $464.47 | -1.0% | -0.9% | +0.8% | -1.7% | -0.2% | +1.1% |
| Feb 4 | Morgan Stanley | Maintains | Overweight → Overweight | — | $469.04 | $464.47 | -1.0% | -0.9% | +0.8% | -1.7% | -0.2% | +1.1% |
| Feb 3 | Stifel | Maintains | Hold → Hold | — | $422.05 | $465.00 | +10.2% | +11.1% | -0.9% | +0.8% | -1.7% | -0.2% |
| Jan 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $417.86 | $417.95 | +0.0% | +0.2% | +1.3% | -0.5% | +11.1% | -0.9% |
| Nov 4 | Barclays | Maintains | Overweight → Overweight | — | $417.28 | $419.36 | +0.5% | -0.7% | +0.4% | +1.8% | +2.3% | +0.1% |
| Nov 4 | Piper Sandler | Maintains | Neutral → Neutral | — | $417.28 | $419.36 | +0.5% | -0.7% | +0.4% | +1.8% | +2.3% | +0.1% |
| Oct 11 | JP Morgan | Maintains | Overweight → Overweight | — | $473.28 | $474.92 | +0.3% | +0.6% | +0.4% | -0.9% | -2.1% | -0.8% |
| Oct 10 | Stifel | Maintains | Hold → Hold | — | $474.65 | $468.00 | -1.4% | -0.3% | +0.6% | +0.4% | -0.9% | -2.1% |
| Aug 14 | Piper Sandler | Maintains | Neutral → Neutral | — | $487.82 | $485.51 | -0.5% | -2.6% | +2.2% | +1.4% | +1.0% | -0.6% |
| Jun 24 | Stifel | Maintains | Hold → Hold | — | $495.73 | $494.40 | -0.3% | -0.9% | -0.1% | -0.5% | +1.1% | -1.4% |
| May 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $503.02 | $505.76 | +0.5% | +3.6% | +5.3% | -1.4% | +0.5% | -2.5% |
| May 2 | Barclays | Maintains | Overweight → Overweight | — | $468.04 | $465.60 | -0.5% | +1.7% | +1.0% | -0.8% | +1.4% | +0.7% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $572.12 | $575.96 | +0.7% | -0.9% | +0.9% | +0.2% | -0.2% | -1.2% |
| Feb 6 | Barclays | Maintains | Overweight → Overweight | — | $572.12 | $575.96 | +0.7% | -0.9% | +0.9% | +0.2% | -0.2% | -1.2% |
| Jan 30 | Piper Sandler | Downgrade | Overweight → Neutral | — | $532.06 | $520.80 | -2.1% | -2.1% | -1.1% | +2.4% | -0.0% | +8.5% |
| Jan 17 | Goldman Sachs | Maintains | Buy → Buy | — | $520.00 | $516.23 | -0.7% | -0.9% | +1.9% | -0.3% | +1.5% | +0.0% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $429.30 | $430.92 | +0.4% | -1.5% | -0.1% | +1.2% | -2.1% | +2.4% |
| Nov 3 | Goldman Sachs | Maintains | Buy → Buy | — | $419.44 | $425.04 | +1.3% | +2.4% | -1.5% | -0.1% | +1.2% | -2.1% |
| Nov 2 | Barclays | Maintains | Overweight → Overweight | — | $395.35 | $401.17 | +1.5% | +6.1% | +2.4% | -1.5% | -0.1% | +1.2% |
| Nov 2 | JP Morgan | Maintains | Overweight → Overweight | — | $395.35 | $401.17 | +1.5% | +6.1% | +2.4% | -1.5% | -0.1% | +1.2% |
| Oct 30 | Stifel | Maintains | Hold → Hold | — | $391.37 | $394.10 | +0.7% | +1.3% | +0.8% | -1.0% | +6.1% | +2.4% |
| Sep 15 | Stifel | Maintains | Hold → Hold | — | $462.08 | $456.46 | -1.2% | -2.5% | -0.1% | +1.6% | -0.4% | -3.7% |
No insider trades available.
8-K · 2.02
!! High
IDEXX Laboratories, Inc. -- 8-K 2.02: Earnings Results
IDEXX Laboratories reported quarterly earnings results, with full details available in the accompanying press release, providing investors insight into the company's operational performance and financial health.
May 5
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
IDXX's departure of a key executive, with accelerated vesting of equity awards, signals leadership transition costs and potential talent loss that could impact operational execution and shareholder value.
Mar 26
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Abbott Laboratories' appointment of a new executive effective April 1, 2026, signals potential strategic shifts in operations or leadership direction that could affect near-term stock performance and investor confidence in company management.
Mar 18
8-K
DENTSPLY SIRONA Inc. -- 8-K Filing
DENTSPLY SIRONA strengthened its board with three experienced executives from dental and financial sectors, including Morgan Stanley's former investment banking leader and IDEXX's ex-CFO, signaling potential strategic shifts ahead.
Feb 26
8-K · 5.02
!!! Very High
DENTSPLY SIRONA Inc. -- 8-K 5.02: Executive Change
DENTSPLY SIRONA appointed James D. Forbes as director while Willie A. Deese resigned, signaling potential strategic shifts in board composition and governance priorities.
Feb 24
8-K · 5.02
!!! Very High
Idexx Laboratories Inc -- 8-K 5.02: Executive Change
IDEXX Laboratories announces board member Anne Szostak's retirement, with no reported disagreements concerning company operations or policies.
Feb 13
8-K · 5.02
!!! Very High
Piper Sandler Companies -- 8-K 5.02: Executive Change
Piper Sandler Companies appointed Stuart M. Essig as a director, expanding its board leadership potentially with his industry expertise.
Feb 4
8-K
Idexx Laboratories Inc -- 8-K Filing
IDEXX Laboratories reported fourth quarter 2025 revenue growth of 14% as reported and 12% organically, driven by strong performance in its CAG Diagnostics recurring revenue segment.
Feb 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 5,182,507 | $2.9B | New | Mar 2026 |
| 2 | Vanguard Portfolio Management Llc | 3,910,863 | $2.2B | New | Mar 2026 |
| 3 | Morgan Stanley | 3,107,462 | $2.1B | Reduced | Dec 2025 |
| 4 | Invesco Ltd. | 1,678,556 | $943M | Added | Mar 2026 |
| 5 | Bank Of New York Mellon Corp | 1,504,532 | $845M | Reduced | Mar 2026 |
| 6 | Principal Financial Group Inc | 968,946 | $656M | Reduced | Dec 2025 |
| 7 | Blair William & Co/il | 946,336 | $532M | Reduced | Mar 2026 |
| 8 | Northern Trust Corp | 911,893 | $512M | Reduced | Mar 2026 |
| 9 | Arrowstreet Capital, Limited Partnership | 838,839 | $471M | Added | Mar 2026 |
| 10 | Capital Research Global Investors | 781,345 | $439M | Added | Mar 2026 |
| 11 | Jpmorgan Chase & Co | 779,882 | $434M | Added | Mar 2026 |
| 12 | Polen Capital Management Llc | 695,811 | $391M | Reduced | Mar 2026 |
| 13 | Franklin Resources Inc | 662,633 | $372M | Added | Mar 2026 |
| 14 | Amundi | 610,779 | $343M | New | Mar 2026 |
| 15 | Capital World Investors | 497,851 | $280M | New | Mar 2026 |
| 16 | Bank Of America Corp /de/ | 488,017 | $274M | — | Mar 2026 |
| 17 | Nuveen, Llc | 445,804 | $250M | Reduced | Mar 2026 |
| 18 | Capital Counsel Llc/ny | 420,195 | $236M | Reduced | Mar 2026 |
| 19 | Royal Bank Of Canada | 391,704 | $220M | Reduced | Mar 2026 |
| 20 | Cibc Bancorp Usa Inc. | 367,502 | $207M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity 500 Index Fund | 1,016,204 | $667M | Feb 2026 |
| 2 | iShares Core S&P 500 ETF | 1,027,534 | $577M | Mar 2026 |
| 3 | MidCap Fund | 528,699 | $354M | Jan 2026 |
| 4 | iShares Russell Mid-Cap Growth ETF | 534,598 | $300M | Mar 2026 |
| 5 | BlackRock Mid-Cap Growth Equity Portfolio | 308,714 | $203M | Feb 2026 |
| 6 | Invesco NASDAQ 100 ETF | 303,679 | $199M | Feb 2026 |
| 7 | iShares Russell 1000 Growth ETF | 321,242 | $181M | Mar 2026 |
| 8 | Ultra Fund | 257,000 | $172M | Jan 2026 |
| 9 | iShares Russell Mid-Cap ETF | 304,554 | $171M | Mar 2026 |
| 10 | iShares MSCI USA Quality Factor ETF | 255,002 | $171M | Jan 2026 |
| 11 | Invesco S&P 500 Equal Weight ETF | 226,815 | $152M | Jan 2026 |
| 12 | BARON ASSET FUND | 269,176 | $151M | Mar 2026 |
| 13 | iShares U.S. Medical Devices ETF | 250,804 | $141M | Mar 2026 |
| 14 | JPMorgan Mid Cap Growth Fund | 239,371 | $135M | Mar 2026 |
| 15 | Baron Focused Growth Fund | 238,900 | $134M | Mar 2026 |
| 16 | Invesco S&P 500 Quality ETF | 179,927 | $121M | Jan 2026 |
| 17 | Schwab S&P 500 Index Fund | 178,926 | $120M | Jan 2026 |
| 18 | BARON GROWTH FUND | 200,000 | $112M | Mar 2026 |
| 19 | Polen Growth Fund | 164,875 | $111M | Jan 2026 |
| 20 | Invesco Discovery Mid Cap Growth Fund | 161,922 | $109M | Jan 2026 |
Valuation
Market Cap
$45.35B
Enterprise Value
$45.64B
P/E (TTM)
42.97x
Forward P/E
38.74x
PEG Ratio
2.30x
P/B
28.04x
P/S
10.54x
P/FCF
43.05x
EV/EBITDA
31.07x
Shares Out
80.7M
Financials (TTM)
Revenue
$4.30B
Net Income
$1.06B
EBITDA
$1.47B
Free Cash Flow
$1.05B
Op Cash Flow
$1.18B
EPS Basic
$13.17
EPS Diluted
$13.08
EPS Forward
$14.51
Gross Margin
61.8%
Op Margin
31.6%
Net Margin
24.6%
Balance Sheet
Total Assets
$3.35B
Total Liab.
$1.75B
Total Equity
$1.61B
Cash
$180.1M
LT Debt
$476.0M
Book Value/Sh
$20.04
Debt/Equity
0.67x
Current Ratio
1.17
Quick Ratio
0.84
Returns & Growth
ROE
66.0%
ROA
31.6%
ROIC
40.3%
Rev Growth YoY
+10.4%
EPS Growth YoY
+22.3%
Price Returns
2W
+5.8%
1M
+0.5%
3M
-14.2%
6M
-25.2%
12M
+9.8%
Technicals
52W High
$766.68
52W Low
$514.61
50d MA
$561.85
200d MA
$632.52
RSI (14)
49.50
ATR (14)
$15.50
Beta
1.72
Avg Volume
646K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$773.13
High
$830.00
Low
$640.00
Median
$792.50
Data updated apr 25, 2026 2:59pm
· Source: financialmodelingprep.com